INTERNATIONAL & USA PRESS INQUIRIES

Please contact David Fraser for international media inquiries

Please contact Corey Henry for USA media inquiries

April 27, 2022

Philip Morris International Inc. to Host Webcast of 2022 Virtual Annual Meeting of Shareholders

download

NEW YORK--(BUSINESS WIRE)--Apr. 27, 2022-- Regulatory News:

Philip Morris International Inc. (NYSE: PM) will host a live audio webcast of its 2022 Annual Meeting of Shareholders on Wednesday, May 4, 2022, at 9:00 a.m. ET. The meeting will be held in a virtual format only, including closed captioning, and can be accessed at www.virtualshareholdermeeting.com/PMI2022.

During the meeting, André Calantzopoulos, Executive Chairman of the Board, and Jacek Olczak, Chief Executive Officer, will address shareholders and answer questions. Only shareholders of record with a valid 16-digit control number will be allowed to ask a question or make a comment.

The audio webcast may also be accessed on iOS or Android devices by downloading PMI’s free Investor Relations Mobile Application at www.pmi.com/irapp.

An archived copy of the webcast will be available for approximately one year from the date of the meeting at www.virtualshareholdermeeting.com/PMI2022.

Presentation slides and script will also be available at www.virtualshareholdermeeting.com/PMI2022.

Philip Morris International: Delivering a Smoke-Free Future

Philip Morris International (PMI) is a leading international tobacco company working to deliver a smoke-free future and evolving its portfolio for the long-term to include products outside of the tobacco and nicotine sector. The company’s current product portfolio primarily consists of cigarettes and smoke-free products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the U.S. Since 2008, PMI has invested more than USD 9 billion to develop, scientifically substantiate and commercialize innovative smoke-free products for adults who would otherwise continue to smoke, with the goal of completely ending the sale of cigarettes. This includes the building of world-class scientific assessment capabilities, notably in the areas of pre-clinical systems toxicology, clinical and behavioral research, as well as post-market studies. The U.S. Food and Drug Administration (FDA) has authorized the marketing of versions of PMI’s IQOS Platform 1 devices and consumables as Modified Risk Tobacco Products (MRTPs), finding that exposure modification orders for these products are appropriate to promote the public health. As of March 31, 2022, PMI's smoke-free products are available for sale in 71 markets, and PMI estimates that approximately 12.7 million adults around the world excluding Russia and Ukraine, have already switched to IQOS and stopped smoking. With a strong foundation and significant expertise in life-sciences, in February 2021 PMI announced its ambition to expand into wellness and healthcare areas and deliver innovative products and solutions that aim to address unmet consumer and patient needs. For more information, please visit www.pmi.com and www.pmiscience.com.

Philip Morris International

Investor Relations:
New York: +1 (917) 663 2233
Lausanne: +41 (0)58 242 4666
Email: InvestorRelations@pmi.com

Media: David Fraser
Lausanne: +41 (0)58 242 4500
Email: David.Fraser@pmi.com

Source: Philip Morris International